2025-08149RuleWallet

FDA Classifies STI Detection Device for Quicker Patient Access

Published Date: 5/9/2025

Rule

Summary

The FDA is officially classifying devices that detect DNA from non-viral germs causing sexually transmitted infections (STIs) and their resistance markers as Class II, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps companies bring these important tests to patients faster and safer, starting May 9, 2025. Labs, device makers, and patients will all benefit from quicker access to innovative STI testing without extra red tape.

Analyzed Economic Effects

5 provisions identified: 3 benefits, 2 costs, 0 mixed.

Clinical Study and Documentation Requirements

The special controls require detailed design verification and validation, including analytical studies and clinical study results with prospective samples for each claimed specimen type, a predefined statistical analysis plan, and documentation of software impacts (21 CFR 866.3393(b)(4) and (3)(iii)-(iv)).

Faster Access to STI DNA Tests

The FDA officially classifies tests that detect DNA from non-viral germs causing sexually transmitted infections and their resistance markers as Class II with special controls, effective May 9, 2025 (classification was applicable January 23, 2019). The agency says this classification reduces regulatory burdens and will help patients get innovative STI tests more quickly.

Enables 510(k) Predicate Use

When FDA classifies this device type via De Novo, that device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) process instead of premarket approval. The final order codifies the device type into 21 CFR 866.3393 and notes the device is subject to premarket notification requirements under section 510(k) of the FD&C Act.

Sample-Collection Devices Must Be Cleared

Any sample collection device used with these tests must be FDA-cleared, -approved, or -classified as 510(k) exempt for the claimed specimen types, or must be cleared in the premarket submission as part of the test. This requirement is set out in the special controls at 21 CFR 866.3393(b)(2).

Labeling Must Warn About Test Limits

The device labeling must include statements that a negative test does not rule out infection, results should be interpreted with other clinical data, and detection of resistance markers does not prove antibiotic susceptibility. The special controls (21 CFR 866.3393(b)(3)(iv) and (b)(3)(v)) spell out these limiting statements for users and clinicians.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
5/9/2025
5/9/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register